News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
697,329 Results
Type
Article (41465)
Company Profile (294)
Press Release (655570)
Section
Business (209643)
Career Advice (2059)
Deals (36549)
Drug Delivery (89)
Drug Development (82543)
Employer Resources (170)
FDA (16374)
Job Trends (15329)
News (354283)
Policy (33778)
Tag
Academia (2572)
Africa (774)
Alliances (50930)
Alzheimer's disease (1152)
Approvals (16311)
Arizona (176)
Artificial intelligence (75)
Asia (39591)
Australia (6311)
Bankruptcy (360)
Best Places to Work (11363)
Biosimilars (66)
Biotechnology (187)
C2C Services and Suppliers (79729)
California (1660)
Canada (864)
Cancer (348)
Career advice (1721)
Cell therapy (104)
China (122)
Clinical research (64488)
Collaboration (114)
Colorado (67)
Compensation (61)
Connecticut (67)
COVID-19 (2549)
Cystic fibrosis (74)
Data (170)
Diabetes (70)
Diagnostics (6032)
Drug pricing (69)
Earnings (85299)
Employer resources (145)
Europe (84052)
Events (110354)
Executive appointments (115)
FDA (16561)
Florida (230)
Funding (110)
Gene therapy (89)
GLP-1 (528)
Government (4399)
Healthcare (18762)
Hotbed/Location (489747)
Illinois (244)
Indiana (142)
Infectious disease (2573)
Inflammatory bowel disease (90)
Interviews (316)
IPO (16450)
Job creations (4046)
Job search strategy (1481)
Kansas (93)
Layoffs (410)
Legal (8289)
Lung cancer (74)
Manufacturing (80)
Maryland (362)
Massachusetts (1393)
Medical device (13103)
Medtech (13106)
Mergers & acquisitions (19917)
Metabolic disorders (232)
Michigan (119)
Minnesota (205)
Neuroscience (1284)
New Jersey (513)
New York (522)
NextGen Class of 2024 (6602)
Non-profit (4499)
North Carolina (587)
Northern California (749)
Obesity (143)
Ohio (98)
Opinion (191)
Patents (66)
Pennsylvania (541)
People (57688)
Pharmaceutical (84)
Phase I (19890)
Phase II (28376)
Phase III (21340)
Pipeline (100)
Postmarket research (2635)
Preclinical (8479)
Press Release (68)
Rare diseases (121)
Real estate (6228)
Recruiting (65)
Regulatory (21982)
Research institute (2350)
Resumes & cover letters (354)
South America (1151)
Southern California (668)
Startups (3704)
Texas (204)
United States (7832)
Vaccines (468)
Washington State (240)
Weight loss (127)
Date
Today (7)
Last 7 days (583)
Last 30 days (2118)
Last 365 days (37770)
2024 (25420)
2023 (40628)
2022 (51797)
2021 (56332)
2020 (54795)
2019 (47400)
2018 (35772)
2017 (33139)
2016 (32662)
2015 (38617)
2014 (32517)
2013 (27631)
2012 (29731)
2011 (30487)
2010 (28497)
697,329 Results for "merrimack pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
Merrimack Pharmaceuticals, Inc. announced that the stockholders at a Special Meeting held overwhelmingly approved adopting a Plan of Dissolution.
May 10, 2024
·
6 min read
Deals
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of Dissolution is obtained at the Special Meeting of Stockholders held on May 10, 2024.
May 9, 2024
·
9 min read
Genetown
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
Merrimack Pharmaceuticals, Inc. announced that it has filed notice with NASDAQ of the Company’s intent to delist its securities from NASDAQ, subject to receipt of stockholder approval of the Plan of Dissolution at the Special Meeting of Stockholders of Merrimack scheduled to be held on Friday, May 10, 2024.
April 30, 2024
·
10 min read
Genetown
Merrimack Reports Full Year 2023 Financial Results
Merrimack Pharmaceuticals, Inc. announced its full year 2023 financial results for the period ended December 31, 2023.
March 7, 2024
·
7 min read
Genetown
Merrimack Receives $225 Million Milestone Payment from Ipsen
Merrimack Pharmaceuticals, Inc. announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug Administration, or FDA, to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas.
March 27, 2024
·
9 min read
Business
Merrimack Reports Third Quarter 2023 Financial Results
Merrimack Pharmaceuticals, Inc. announced its third quarter 2023 financial results for the period ended September 30, 2023.
November 2, 2023
·
6 min read
Policy
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma
Merrimack Pharmaceuticals, Inc. reported that Ipsen, SA issued a press release announcing the U.S. Food and Drug Administration has approved the supplemental new drug application for Onivyde® plus 5 fluorouracil/leucovorin and oxaliplatin as a first-line treatment for people living with metastatic pancreatic ductal adenocarcinoma.
February 13, 2024
·
12 min read
Business
Merrimack Reports Second Quarter 2023 Financial Results
Merrimack Pharmaceuticals, Inc. announced its second quarter 2023 financial results for the period ended June 30, 2023.
August 3, 2023
·
9 min read
Business
Merrimack Reports First Quarter 2023 Financial Results
Merrimack Pharmaceuticals, Inc. announced its first quarter 2023 financial results for the period ended March 31, 2023.
May 4, 2023
·
9 min read
Press Releases
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).
July 1, 2024
·
5 min read
1 of 69,733
Next